> Detailanzeige

Brink, Mirian; Kahle, Xaver U.; Vermaat, Joost S. P.; Zijlstra, Josee M.; Chamuleau, Martine; Kersten, Marie José; Durmaz, Müjde; Plattel, Wouter J.; Lugtenburg, Pieternella J.; Stevens, Wendy; Mous, Rogier; de Vries, Elisabeth G. E.; van der Poel, Marjolein W. M.; Panday, Prashant V. Nannan; Huls, Gerwin; van Meerten, Tom; Nijland, Marcel

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study
  • Beteiligte: Brink, Mirian; Kahle, Xaver U.; Vermaat, Joost S. P.; Zijlstra, Josee M.; Chamuleau, Martine; Kersten, Marie José; Durmaz, Müjde; Plattel, Wouter J.; Lugtenburg, Pieternella J.; Stevens, Wendy; Mous, Rogier; de Vries, Elisabeth G. E.; van der Poel, Marjolein W. M.; Panday, Prashant V. Nannan; Huls, Gerwin; van Meerten, Tom; Nijland, Marcel
  • Erschienen: American Society of Hematology, 2021
  • Erschienen in: Blood Advances
  • Sprache: Englisch
  • DOI: 10.1182/bloodadvances.2021004295
  • ISSN: 2473-9529; 2473-9537
  • Schlagwörter: Hematology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:p>In 2017, the European Medicines Agency approved rituximab biosimilars (R-biosimilars) for treatment of diffuse large B-cell lymphoma (DLBCL). Thereafter, the Netherlands was one of the first countries to implement R-biosimilars, given lower costs compared with rituximab originator (R-originator). This study’s objective was to investigate whether overall survival (OS) of patients with DLBCL receiving R-biosimilars is similar to patients treated with R-originator. DLBCL patients ≥18 years, diagnosed between 2014 and 2018, who received at least 1 cycle of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were identified in the Netherlands Cancer Registry. Patients were categorized into R-originator or R-biosimilars groups based on data from a central repository of the Dutch medicinal drug market. The primary end point was 3-year OS, defined as the time between diagnosis and all-cause death. By the end of 2018, 91% of purchased rituximab were biosimilars. In total, 4429 patients were identified with 876 in the R-biosimilars group and 3553 in the R-originator group. Patients in the R-biosimilars group less frequently received &amp;gt;6 cycles of R-CHOP compared with patients treated with R-originator (24% vs 30%, P = .003). The 3-year OS did not differ between patients treated with R-originator or R-biosimilars (73% vs 73%, P = .855). This was confirmed with a multivariable Cox regression analysis accounting for sex, age, International Prognostic Index score, and number of R-CHOP cycles. In conclusion, the 3-year OS is similar for patients treated with CHOP in combination with R-originator or R-biosimilars and, therefore, favors the use of R-biosimilars in DLBCL treatment management.</jats:p>
  • Zugangsstatus: Freier Zugang